RedHill Biopharma share price logo

RedHill Biopharma

NASDAQ: RDHL

$0.61

+0.02

(+2.93%)

as on

RedHill Biopharma Stock Performance

as on August 20, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.58
    $0.63
    downward going graph

    4.96%

    Downside

    3.23%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.58
    $2.79
    downward going graph

    4.98%

    Downside

    357.15%

    Upside

    downward going graph

RedHill Biopharma share price movements today

Previous Close
$0.59
Open
$0.58
Volume
209.6K
Market Cap
$3.6M
Day's Low - High
$0.58 - $0.63
52 Week Low - High
$0.58 - $2.79

RedHill Biopharma Historical Returns

1 Month Return
-14.91 %
3 Month Return
-41.76 %
1 Year Return
-55.89 %
3 Year Return
-97.42 %
5 Year Return
-99.99 %

RedHill Biopharma Stock Fundamentals & Key Indicators

Check RedHill Biopharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.6M

EPS (TTM)

-4

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.3

Industry PE ratio

-3.7182758620689653

PEG Ratio

-0.0016876649076517144

EBITDA

-7.9M

Revenue (TTM)

9.5M

Profit Margin

60.60%

Return On Equity TTM

5740.28%

RedHill Biopharma Stock Valuation

Track how RedHill Biopharma P/E has moved over time to understand its valuation trends.

RedHill Biopharma in the last 5 years

  • Overview

  • Trends

Lowest (-7.58x)

December 31, 2025

Today (-7.58x)

December 31, 2025

Industry (-3.72x)

December 31, 2025

Highest (0.79x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -7.58x

RedHill Biopharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of RedHill Biopharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
RedHill Biopharma image
RedHill Biopharma
BUY$3.6M-99.99%-0.360.60%NA
United Therapeutics image
United Therapeutics
BUY$21.4B145.28%16.5886.14%NA
Viatris image
Viatris
HOLD$18.6B9.88%-44.5634.83%2.9899999999999998%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
BUY$42.7BNA19.814.55%126.42999999999999%
Zoetis image
Zoetis
BUY$30.5B-64.28%12.4770.87%2.76%
See all

Stock Returns calculator for RedHill Biopharma Stock including INR - Dollar returns

The RedHill Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

RedHill Biopharma investment value today

Current value as on today

₹49,345

Returns

-₹50,655

(-50.66%)

Returns from RedHill Biopharma Stock

-₹55,125 (-55.13%)

Dollar Impact

₹4,470 (+4.47%)

Analyst Recommendation on RedHill Biopharma Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for RedHill Biopharma. Average target price of $19000

RedHill Biopharma Share Price Target

Get share price movements and forecasts by analysts on RedHill Biopharma.

What analysts predicted

100%UPSIDE

Target Price

$19000

Current Price

$0.6103

Analyzed by

7 Analysts

Target

$19000.00

RedHill Biopharma target price $19000, a slight upside of 100% compared to current price of $0.6103. According to 7 analysts rating.

Indian Investors' Interest in RedHill Biopharma Stock

Search interest for RedHill Biopharma Stock has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-22% versus previous 30 day period

RedHill Biopharma Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
3
1
0
0
1
1
2
2
2
2
Gross Profit
1
0
0
0
0
0
1
1
1
1
Operating Income
29
-4
-6
-6
-4
-4
-3
-3
-2
-2
EBITDA
111
2
-5
-5
-4
-4
-1
-1
-2
-2
Interest Expense
0
1
-
-
0
0
-
-
0
0
Depreciation
60
-58
0
0
0
0
0
0
0
0
Income Before Tax
50
0
-13
-13
-1
-1
-2
-2
-2
-2
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
50
0
-13
-13
-1
-1
-2
-2
-2
-2
Net Profit Margin
55.21%
55.12%
8.28%
8.28%
45.41%
45.41%
67.32%
67.32%
60.60%
60.60%

RedHill Biopharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Mar 2023
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
8
6
64
85
61
6
8
0
Gross Profit
1
5
4
27
36
28
3
4
0
Operating Income
-51
-39
-43
-63
-81
-42
12
-14
-7
EBITDA
-45
-38
-40
-54
-63
-22
26
-7
-7
Interest Expense
0
0
0
12
16
41
0
0
0
Depreciation
0
0
1
8
18
8
1
0
0
Income Before Tax
-45
-38
-42
-76
-97
-71
23
-8
-8
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-45
-38
-42
-76
-97
-71
23
-8
0
Net Profit Margin
46.94%
66.06%
64.09%
42.68%
42.39%
46.06%
47.03%
60.31%
100.00%

RedHill Biopharma Quarterly Cash Flow

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
50
0
-13
-13
-1
-1
-2
-2
-2
-2
Operating Cash Flow
-7
-10
-9
-9
-3
-3
-1
-1
-2
-2
Investing Cash Flow
-
0
0
0
0
0
0
0
0
0
Financing Cash Flow
4
0
8
8
3
3
0
0
1
1
Change in Cash
-2
-10
-6
-
-
7
-7
-
-
-

RedHill Biopharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Mar 2023
Dec 2023
Dec 2024
Dec 2025
Net Income
-45
-38
-42
-76
-97
-71
23
-8
0
Operating Cash Flow
-44
-34
-40
-48
-65
-29
-35
-9
-9
Investing Cash Flow
-18
5
5
-35
-8
8
0
0
1
Financing Cash Flow
25
41
35
84
73
11
21
8
7
Change in Cash
-37
12
0
0
0
-9
-14
0
0

Global Institutional Holdings in RedHill Biopharma

Funds
Holdings
Advisor Group Holdings, Inc.
0%
Yorkville Advisors Global, LP
2.01%
Group One Trading, LP
0%
Garton & Associates Financial Advisors LLC
0%
Group One Trading, LLC
0%
See all

RedHill Biopharma News & Key Events

  • img

    Today's Timeline - 18 June

    Thu, 05:30 PM

    -

    RedHill Biopharma announces a $19.4 million private placement to fund pipeline and potential acquisitions, closing expected on June 22, 2026.

Insights on RedHill Biopharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -2.59M → -2.06M (in $), with an average increase of 12.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 125.5% return, outperforming this stock by 222.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, United Therapeutics Corporation Common Stock has given 65.5% return, outperforming this stock by 124.6%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, RDHL stock has moved down by -36.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 2.73M → 2.03M (in $), with an average decrease of 12.7% per quarter

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
OrganisationRedHill Biopharma
Headquarters21 Ha?arba?a Street, Tel Aviv-Yafo, Israel, 6473921
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Dror Ben-Asher
E-voting on sharesClick here to vote

Key Management of RedHill Biopharma

Name

Title

Mr. Razi Ingber

Chief Financial Officer

Mr. Gilead Raday MPhil, MSc

Chief Operating Officer

Dr. Mark L. Levitt M.D., Ph.D.

Chief Scientific Officer

Ms. Alexandra Okmian

Senior Business Development & Investor Relations Manager

Dr. Reza Fathi Ph.D.

Senior Vice President of Research & Development

Mr. Guy Goldberg J.D.

Chief Business Officer

Ms. Patricia Anderson B.Sc. RAC

Senior Vice President of Regulatory Affairs

Mr. Dror Ben-Asher

Co-Founder, Chairman & CEO

Mr. Rick D. Scruggs

Chief Commercial Officer & Director

Mr. Adi Frish

Chief Corporate & Business Development Officer

FAQs

What is RedHill Biopharma share price today?

RedHill Biopharma share price today is $0.61 as on at the close of the market. RedHill Biopharma share today touched a day high of $0.63 and a low of $0.58.

What is the 52 week high and 52 week low for RedHill Biopharma share?

RedHill Biopharma share touched a 52 week high of $2.79 on and a 52 week low of $0.58 on . RedHill Biopharma stock price today i.e. is closed at $0.61,which is 78.13% down from its 52 week high and 5.24% up from its 52 week low.

What is RedHill Biopharma's market capitalisation today?

RedHill Biopharma market capitalisation is $0.00T as on .

How to invest in RedHill Biopharma Stock (RDHL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for RedHill Biopharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in RedHill Biopharma Shares that will get you 2.4578 shares as per RedHill Biopharma share price of $0.61 per share as on August 20, 2026 at 1:29 am IST.

What is the minimum amount required to buy RedHill Biopharma Stock (RDHL) from India?

Indian investors can start investing in RedHill Biopharma (RDHL) shares with as little as ₹95.743 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.43 in RedHill Biopharma stock (as per the Rupee-Dollar exchange rate as on ). Based on RedHill Biopharma share’s latest price of $0.61 as on August 20, 2026 at 1:29 am IST, you will get 16.3854 shares of RedHill Biopharma. Learn more about fractional shares .

What are the returns that RedHill Biopharma has given to Indian investors in the last 5 years?

RedHill Biopharma stock has given -99.99% share price returns and 28.54% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?